Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sunshine Biopharma (SBFM) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Sunshine Biopharma (SBFM) over the last 10 years, with Q3 2025 value amounting to 0.26%.

  • Sunshine Biopharma's Return on Capital Employed fell 600.0% to 0.26% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.26%, marking a year-over-year decrease of 600.0%. This contributed to the annual value of 0.26% for FY2024, which is 500.0% down from last year.
  • Latest data reveals that Sunshine Biopharma reported Return on Capital Employed of 0.26% as of Q3 2025, which was down 600.0% from 0.26% recorded in Q2 2025.
  • Sunshine Biopharma's Return on Capital Employed's 5-year high stood at 0.1% during Q3 2022, with a 5-year trough of 3.09% in Q1 2021.
  • For the 5-year period, Sunshine Biopharma's Return on Capital Employed averaged around 0.75%, with its median value being 0.26% (2025).
  • In the last 5 years, Sunshine Biopharma's Return on Capital Employed tumbled by -39000bps in 2021 and then surged by 27800bps in 2022.
  • Sunshine Biopharma's Return on Capital Employed (Quarter) stood at 1.08% in 2021, then rose by 11bps to 0.96% in 2022, then surged by 77bps to 0.22% in 2023, then decreased by -10bps to 0.24% in 2024, then decreased by -8bps to 0.26% in 2025.
  • Its Return on Capital Employed stands at 0.26% for Q3 2025, versus 0.26% for Q2 2025 and 0.24% for Q1 2025.